PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment

PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Dettagli Bibliografici
Autore principale: Lubaba, Anikah
Altri autori: Fariha, Luluel Maknun
Natura: Tesi
Lingua:English
Pubblicazione: Brac University 2024
Soggetti:
Cardiovascular disease
CVD
Cholesterol-lowering therapy
Hyperlipidemia
Monoclonal antibody
PCSK9
Heart > Diseases > Treatment
Coronary heart disease > Treatment
Cholesterol > Pathophysiology
Accesso online:http://hdl.handle.net/10361/23252

Accesso online

http://hdl.handle.net/10361/23252

Documenti analoghi